Sign up


Match Document Document Title
8911777 Pharmaceutical composition of tacrolimus  
An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized...
8912158 Method for treating myocardial infarct  
The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order...
8912155 Method for analyzing secretome, biomarker for lung cancer metastasis, and siRNA compound for inhibiting lung cancer metastasis  
A method for analyzing secretome, a biomarker for lung cancer metastasis, and a siRNA compound for inhibiting lung cancer metastasis are disclosed. The method for analyzing secretome of the present...
8912160 Methods for treating hypercholesterolemia  
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating,...
8912159 Analyzing semaphorin7a (Sema7A) levels for assessing cancer metastatic potential and methods of treatment  
Methods, assays, and kits for determining a cancer's (e.g., breast cancer) metastatic potential and tumor aggressiveness in a subject (e.g., a human patient) and for measuring a subject's response...
8906871 MicromiRs  
The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
8906877 Method for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis  
Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that...
8906870 MicroRNA (miRNA) for the diagnosis and treatment of heart diseases  
The invention relates to microRNAs (miRNAs) for the diagnosis, prophylaxis and/or treatment of heart diseases. It relates in particular to SEQ ID No: 1 to SEQ ID No: 29 for the diagnosis,...
8907077 siRNA targeting TIE-2  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
8900627 Compositions for the in vivo delivery of RNAi agents  
This application describes emulsion formulations containing neutral phospholipids for delivering RNAi, anti-miRNA, or aptamer agents in vivo. The application also relates to methods of making the...
8901098 Antisense modulation of GCCR expression  
Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent,...
8901097 Methods for delivery of siRNA to the spinal cord and therapies arising therefrom  
The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of...
8901101 Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides  
The present invention provides membrane lytic poly(amido amine) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.
8895521 Methods and compositions for the treatment of uveitis  
Pharmaceutical compositions are disclosed that are of use for the treatment of uveitis. These compositions include a suppressive oligonucleotide. These compositions including an immunosuppressive...
8895529 Antisense modulation of fibroblast growth factor receptor 4 expression  
Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly...
8895524 Viral microRNA  
The present invention relates, in general, to micro RN As and, in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit...
8895527 Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2)...
8895526 Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers  
Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is...
8889648 Nucleic acid having an anti-metabolic syndrome effect  
The problem of the present invention is to prove a medicament for decreasing body weigh, a medicament for decreasing visceral fat, a medicament for decreasing triglyceride in the liver, and a...
8889649 Composition containing antisense oligonucleotide to micro RNA  
Provided is a composition that contains an antisense oligonucleotide to a micro RNA and is capable of inhibiting the growth of cancer cells. The present invention, as one aspect, relates to a...
8889646 Nucleic acid modulators of glycoprotein VI  
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of...
8889645 Nucleic acid modulators of glycoprotein VI  
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of...
8889640 Composition and method for the treatment of gastrin mediated cancers  
Gastrin mRNA down-regulation using either stable transfection of an antisense gastrin cDNA or one of three shRNA (short hairpin RNA) constructs achieves significant reduction in growth of human...
8889642 Methods and compositions for RNAi-based cancer treatment  
The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers.
8889639 Compositions and methods for modulating PGC-1β to treat lipid-related diseases and disorders  
The present invention provides methods for treating lipid-related diseases and disorders, e.g., hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, cardiovascular disease, obesity, and type...
8883757 Compositions and methods for treatment of ovarian cancer  
The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to...
8883208 Particles for delivery of nucleic acids and related devices and methods  
Embodiments of the invention include devices and methods for the release of nucleic acid complexes. In an embodiment the invention includes a nucleic acid delivery particle. The delivery particle...
8883755 Mitochondrial targeted RNA expression system and use thereof  
Described herein is a mitochondrial-targeted RNA expression system (mtTRES) for delivery of RNA molecules to mitochondria. mtTRES vectors generate RNAs in vivo that are un-capped,...
8877725 Peptide conjugated, inosine-substituted antisense oligomer compound and method  
A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base...
8877729 Amino acid lipids and uses thereof  
This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid...
8877726 Method and medicament for inhibiting the expression of a given gene  
The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using...
8877730 Targeting microRNAs for metabolic disorders  
Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of...
8877237 Reverse micelle system comprising nucleic acids and use thereof  
The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and nucleic acids. The reverse micelle system of the invention is able to...
8871731 Micro-RNA for the regulation of cardiac apoptosis and contractile function  
The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing...
8871729 Treatment of CNS conditions  
Methods and compositions for the treatment of pathologic conditions of the central nervous system (CNS) by means of intranasal administration of a composition that modulates, by means of RNA...
8871730 Chemical modification of short small hairpin RNAs for inhibition of gene expression  
Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed...
8865671 RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions  
RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of...
8865674 Antisense modulation of GCGR expression  
Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent,...
8865670 RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma  
RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enz...
8865677 iRNA agents with biocleavable tethers  
The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more...
8865676 Methods and kits for synthesis of siRNA expression cassettes  
Amplification-based methods and kits for rapidly producing siRNA expression cassettes are provided. Also provided are methods for expressing amplified siRNA expression cassettes in cells.
8865675 Compositions and methods for silencing apolipoprotein B  
The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic...
8865672 Prevention of tissue ischemia and related methods  
Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in...
8859514 Modulation of C-reactive protein expression  
Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive...
8859521 Oligomeric compounds and compositions for use in modulation of small non-coding RNAs  
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding...
8859515 Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural...
8859519 Methods targeting miR-33 microRNAs for regulating lipid metabolism  
Compositions comprising nucleic acid sequences that target MiR-33a/b microRNAs are described, together with uses of the same in the treatment of certain disorders related to elevated serum...
8859516 Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes  
This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and...
8853179 Reengineering mRNA primary structure for enhanced protein production  
Described herein are rules to modify natural mRNAs or to engineer synthetic mRNAs to increase their translation efficiencies. These rules describe modifications to mRNA coding and 3′ UTR s...
8853180 Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides  
This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant...